Natco Pharma Ltd Share Price
(NATCOPHARM)
₹827.6▲0.12%
as on 04:01PM, 17 Apr 2025
Natco Pharma Performance
Day's Low
Day's High
₹817.6Day's Price Range₹83652 Week's Low
52 Week's High
₹726.852-Week Price Range₹1,639
| Returns % | |
| 1 Month Return | + 2.59 % |
| 3 Month Return | -34.21 % |
| 1 Year Return | -16.91 % |
| Market Stats | |
| Previous Close | ₹826.60 |
| Open | ₹826.60 |
| Volume | 3.00L |
| Upper Circuit | ₹991.90 |
| Lower Circuit | ₹661.30 |
| Market Cap | ₹14,823.13Cr |
Natco Pharma Fundamentals
P/E Ratio
7.95
PEG Ratio
0.24
Market Cap
₹14,823.13 Cr
P/B Ratio
3.05
EPS
77.56
Dividend Yield
1
Sector
Pharmaceuticals
ROE
25.38
Mutual Fund Holdings of Natco Pharma
Natco Pharma Analyst Rating
based on 12 analysts
45.45%
Buy
18.18%
Hold
36.36%
Sell
Based on 12 analysts offering long term price targets for Natco Pharma. An average target of ₹1099.33
Source: S&P Global Market Intelligence
Natco Pharma Share analysis
Natco Pharma price forecast by 12 analysts
Upside of32.83%
High
₹1675
Target
₹1099.33
Low
₹710
Natco Pharma target price ₹1099.33, a slight upside of 32.83% compared to current price of ₹827.6. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Natco Pharma revenue growth forecast
Expected growth rate Q1, FY2027:
Forecast
Actual
Including amortisation and stock based compensations
Natco Pharma EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Natco Pharma Ltd
Natco Pharma Updates on Risdiplam and Q3 Results - 08 Apr, 2025
Natco Pharma reported a decline in Q3 FY25 revenue and net profit. The company plans to launch Risdiplam at Rs 15,900, pending court clarity. Legal updates led to a 3% rise in stock price.Natco Pharma Shares Drop Amid Tariff Concerns - 04 Apr, 2025
Natco Pharma shares fell 5% to ₹794.75 as investor sentiment soured after President Trump warned of aggressive pharmaceutical tariffs. The stock's decline reflects concerns over potential scrutiny under U.S. trade laws, impacting the company's significant U.S. revenue.Natco Pharma Shares Surge on U.S. Tariff Exemption - 03 Apr, 2025
Natco Pharma shares rose 5.07% to ₹847.45 after the U.S. exempted Indian generics from new tariffs. With 70% of revenue from the U.S., Natco stands to benefit significantly.Natco Pharma Targets ₹2000 Cr Profit Amid Challenges - 30 Mar, 2025
Natco Pharma aims for ₹1,800 to ₹2,000 crore PAT in FY25 and FY26 despite a 37.41% revenue decline in Q3FY25. The company plans to expand globally and launch key oncology products, while facing price erosion in Revlimid. Recent trading saw a 3% drop in share price.Delhi HC Halts Natco Pharma's Risdiplam Launch - 26 Mar, 2025
The Delhi High Court has instructed Natco Pharma to pause the launch of its generic Risdiplam until April 2 due to a patent dispute with Roche.Delhi HC Clears Path for Natco's Generic Risdiplam - 25 Mar, 2025
The Delhi High Court's ruling permits Natco Pharma to produce a generic version of Risdiplam, significantly lowering treatment costs for spinal muscular atrophy in India.
Insights on Natco Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 26.12% to 26.87% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 17.51% to 17.94% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, NATCOPHARM stock has moved up by 6.6%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 49.62% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 55.1% return, outperforming this stock by 72.2%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 125.9% return, outperforming this stock by 121.4%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 1.43K Cr → 651.1 Cr (in ₹), with an average decrease of 54.6% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 2.37% to 1.92% in Dec 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 677.3 Cr → 133.0 Cr (in ₹), with an average decrease of 80.4% per quarter
Natco Pharma Financials
Natco Pharma Index Inclusions
Natco Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 49.62% | 0.00 | |
| Foreign Institutions | 17.94% | 2.44 | |
| Mutual Funds | 1.92% | ||
| Retail Investors | 26.87% | 2.88 | |
| Others | 3.66% |
Natco Pharma Key Indicators
Natco Pharma Valuation
Natco Pharma in the last 5 years
Lowest (7.17x)
April 9, 2025
Today (7.95x)
April 17, 2025
Industry (53.02x)
April 17, 2025
Highest (90.32x)
April 6, 2022
Natco Pharma Earnings and Dividends
Natco Pharma Ltd Earnings Results
Natco Pharma Ltd’s net profit fell -37.47% since last year same period to ₹133Cr in the Q3 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated -80.36% fall in its net profits since last 3-months.
Read More about Earnings ResultsNatco Pharma Ltd Dividends February,2025
In the quarter ending December 2024, Natco Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.88%.
Read More about Dividends
Natco Pharma Technicals Summary
Bearish
Neutral
Bullish
Natco Pharma Ltd is currently in a Neutral trading position according to technical analysis indicators.
Natco Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹14,823.13 Cr | 6.86% | 0.54 | ₹1,388 Cr | ₹3,998 Cr | |
| BUY | ₹14,328.11 Cr | -3.72% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹68,648.57 Cr | 23.32% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹83,673.39 Cr | 29.91% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹65,216.25 Cr | 16.36% | 0.53 | NA | NA |
About Natco Pharma
Revenue: ₹474.80Cr as on December 2024 (Q4 24)
Net Profit: ₹132.40Cr as on December 2024 (Q4 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
| Organisation | Natco Pharma |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Natco Pharma Ltd
What is Natco Pharma Ltd price today?
Natco Pharma Ltd share price today stands at ₹827.6, Open: ₹826.6, Previous Close: ₹826.6, High: ₹836, Low: ₹817.6, 52 Week High: ₹1639, 52 Week Low: ₹726.8.
How to Buy Natco Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Natco Pharma Ltd shares
What are today's traded volumes of Natco Pharma Ltd?
Today's traded volume of Natco Pharma Ltd(NATCOPHARM) is 3.00L.
What is today's market capitalisation of Natco Pharma Ltd?
Today's market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹14823.13Cr.
What is the 52 Week High and Low Range of Natco Pharma Ltd?
How much percentage Natco Pharma Ltd is down from its 52 Week High?
Natco Pharma Ltd (NATCOPHARM) share price is ₹827.6. It is down -49.51% from its 52 Week High price of ₹1639
How much percentage Natco Pharma Ltd is up from its 52 Week low?
Natco Pharma Ltd (NATCOPHARM) share price is ₹827.6. It is up 13.87% from its 52 Week Low price of ₹726.8